{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:07:08Z","timestamp":1772856428820,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fiji Health Sector Support Project"},{"name":"Australian Aid-JTA, the Department of Foreign Affairs and Trade, Australia"},{"name":"Victorian Government's Operational Infrastructure Support Program"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.vaccine.2015.07.102","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T09:30:25Z","timestamp":1439199025000},"page":"5042-5050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-5837","authenticated-orcid":false,"given":"Zheng Quan","family":"Toh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul V.","family":"Licciardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepehr N.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-9639","authenticated-orcid":false,"given":"Fiona M.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward K.","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"June (12)","key":"10.1016\/j.vaccine.2015.07.102_bib0365","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","article-title":"A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions","volume":"80","author":"Durst","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2015.07.102_bib0370","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ijc.2910520513","article-title":"The causal link between human papillomavirus and invasive cervical cancer: a population-based case\u2013control study in Colombia and Spain","volume":"52","author":"Munoz","year":"1992","journal-title":"Int J Cancer"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2015.07.102_bib0375","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","article-title":"Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group","volume":"87","author":"Bosch","year":"1995","journal-title":"J Natl Cancer Inst"},{"issue":"October (1\u20132)","key":"10.1016\/j.vaccine.2015.07.102_bib0380","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1386-6532(00)00091-3","article-title":"Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report","volume":"19","author":"Schiller","year":"2000","journal-title":"J Clin Virol"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2015.07.102_bib0385","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2015.07.102_bib0390","series-title":"GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012","author":"GLOBOCAN","year":"2012"},{"issue":"May (2 Suppl)","key":"10.1016\/j.vaccine.2015.07.102_bib0395","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2008.02.003","article-title":"Immunobiology of HPV and HPV vaccines","volume":"109","author":"Stanley","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2015.07.102_bib0400","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/aje\/kwg171","article-title":"Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study","volume":"158","author":"Molano","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2015.07.102_bib0405","first-page":"266","article-title":"Immune responses to human papilloma viruses","volume":"130","author":"Stanley","year":"2009","journal-title":"Indian J Med Res"},{"issue":"October (4)","key":"10.1016\/j.vaccine.2015.07.102_bib0410","first-page":"591","article-title":"Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears, New York Cervical Disease Study","volume":"84","author":"Wright","year":"1994","journal-title":"Obstet Gynecol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2015.07.102_bib0415","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0029-7844(95)00408-4","article-title":"Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus","volume":"87","author":"Fruchter","year":"1996","journal-title":"Obstet Gynecol"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2015.07.102_bib0420","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/00002030-199509000-00014","article-title":"HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam","volume":"9","author":"Fennema","year":"1995","journal-title":"AIDS"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2015.07.102_bib0425","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2015.07.102_bib0430","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jnci\/86.7.494","article-title":"A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16","volume":"86","author":"Kirnbauer","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"December (52)","key":"10.1016\/j.vaccine.2015.07.102_bib0435","first-page":"7236","article-title":"WHO position on HPV vaccines","volume":"27","author":"World Health Organization","year":"2009","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2015.07.102_bib0440","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14712598.2011.573624","article-title":"Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile","volume":"11","author":"Garcon","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2015.07.102_bib0445","series-title":"Gardasil 9 prescribing information","author":"Merck & Co., Inc.","year":"2014"},{"issue":"February (8)","key":"10.1016\/j.vaccine.2015.07.102_bib0450","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.07.102_bib0455","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Future I\/II Study Group","year":"2010","journal-title":"BMJ"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2015.07.102_bib0460","first-page":"1915","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Future II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2015.07.102_bib0465","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2015.07.102_bib0470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"issue":"July (9686)","key":"10.1016\/j.vaccine.2015.07.102_bib0475","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"November (9447)","key":"10.1016\/j.vaccine.2015.07.102_bib0480","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"July (27\u201328)","key":"10.1016\/j.vaccine.2015.07.102_bib0485","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"December (11)","key":"10.1016\/j.vaccine.2015.07.102_bib0490","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"issue":"April (9518)","key":"10.1016\/j.vaccine.2015.07.102_bib0495","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2015.07.102_bib0500","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2011.12.009","article-title":"Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine","volume":"53","author":"Rowhani-Rahbar","year":"2012","journal-title":"J Clin Virol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2015.07.102_bib0505","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccines Immunother"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2015.07.102_bib0510","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1542\/peds.2013-4144","article-title":"Long-term study of a quadrivalent human papillomavirus vaccine","volume":"134","author":"Ferris","year":"2014","journal-title":"Pediatrics"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2015.07.102_bib0515","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2015.07.102_bib0520","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2015.07.102_bib0525","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2015.07.102_bib0530","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10\u201318 years","volume":"44","author":"Petaja","year":"2009","journal-title":"J Adolesc Health"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2015.07.102_bib0535","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"issue":"January (3)","key":"10.1016\/j.vaccine.2015.07.102_bib0540","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.vaccine.2010.10.046","article-title":"Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age","volume":"29","author":"Russell","year":"2011","journal-title":"Vaccine"},{"issue":"April (17)","key":"10.1016\/j.vaccine.2015.07.102_bib0545","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.vaccine.2013.02.048","article-title":"Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children","volume":"31","author":"Raczniak","year":"2013","journal-title":"Vaccine"},{"issue":"November (ACS-11)","key":"10.1016\/j.vaccine.2015.07.102_bib0550","first-page":"1","article-title":"Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS)","volume":"33","author":"National Advisory Committee on Immunization","year":"2007","journal-title":"Canada Commun Dis Rep"},{"issue":"May (17)","key":"10.1016\/j.vaccine.2015.07.102_bib0555","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"October (19)","key":"10.1016\/j.vaccine.2015.07.102_bib0560","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"February (6)","key":"10.1016\/j.vaccine.2015.07.102_bib0565","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.vaccine.2013.11.059","article-title":"Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16\/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months","volume":"32","author":"Lazcano-Ponce","year":"2014","journal-title":"Vaccine"},{"issue":"February (5)","key":"10.1016\/j.vaccine.2015.07.102_bib0570","article-title":"Immune response to the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study","volume":"10","author":"Romanowski","year":"2014","journal-title":"Hum Vaccines Immunother"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2015.07.102_bib0575","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccines"},{"issue":"October (47)","key":"10.1016\/j.vaccine.2015.07.102_bib0580","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1016\/j.vaccine.2014.08.071","article-title":"Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda","volume":"32","author":"LaMontagne","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.102_bib0585","series-title":"Eurogin 2013 International Multidisciplinary Congress 2013","first-page":"1","article-title":"Immune responses to a 2-dose schedule of the hpv-16\/18 as04-adjuvanted vaccine in girls (9\u201314) versus 3 doses in women (15\u201325): a randomised trial","author":"Puthanakit","year":"2013"},{"issue":"May (11)","key":"10.1016\/j.vaccine.2015.07.102_bib0590","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types","volume":"110","author":"Kavanagh","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2015.07.102_bib0595","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2015.07.102_bib0600","doi-asserted-by":"crossref","first-page":"g1458","DOI":"10.1136\/bmj.g1458","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case\u2013control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"issue":"October (7)","key":"10.1016\/j.vaccine.2015.07.102_bib0605","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/cid\/cit436","article-title":"Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark","volume":"57","author":"Blomberg","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"February (6)","key":"10.1016\/j.vaccine.2015.07.102_bib0610","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jama.2014.95","article-title":"Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma","volume":"311","author":"Herweijer","year":"2014","journal-title":"JAMA"},{"issue":"October (43)","key":"10.1016\/j.vaccine.2015.07.102_bib0615","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations"},{"key":"10.1016\/j.vaccine.2015.07.102_bib0620","series-title":"WHO weekly epidemiological record","author":"World Health Organization","year":"2014"},{"issue":"February","key":"10.1016\/j.vaccine.2015.07.102_bib0625","article-title":"Inconclusive evidence for non-inferior immunogenicity of two-compared with three-dose HPV immunization schedules in preadolescent girls: a systematic review and meta-analysis","author":"Donken","year":"2015","journal-title":"J Infect"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2015.07.102_bib0630","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4161\/hv.24340","article-title":"Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial","volume":"9","author":"Safaeian","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"September (41)","key":"10.1016\/j.vaccine.2015.07.102_bib0635","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.vaccine.2014.07.014","article-title":"Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes","volume":"32","author":"Barzon","year":"2014","journal-title":"Vaccine"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2015.07.102_bib0640","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2015.07.102_bib0645","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1473-3099(13)70302-5","article-title":"HPV genotype replacement: too early to tell","volume":"13","author":"Pons-Salort","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"May (17)","key":"10.1016\/j.vaccine.2015.07.102_bib0650","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1001\/jama.2013.4147","article-title":"HPV vaccination: too soon for 2 doses?","volume":"309","author":"Kahn","year":"2013","journal-title":"JAMA"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2015.07.102_bib0655","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"September (Pt 9)","key":"10.1016\/j.vaccine.2015.07.102_bib0660","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1099\/0022-1317-80-9-2471","article-title":"A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles","volume":"80","author":"Marais","year":"1999","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.07.102_bib0665","series-title":"Vaccines","first-page":"17","article-title":"Vaccine immunology","author":"Siegrist","year":"2008"},{"issue":"May (24)","key":"10.1016\/j.vaccine.2015.07.102_bib0670","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.vaccine.2012.03.051","article-title":"Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination","volume":"30","author":"Smolen","year":"2012","journal-title":"Vaccine"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2015.07.102_bib0675","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.4049\/jimmunol.182.3.1706","article-title":"Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients","volume":"182","author":"Garcia-Pineres","year":"2009","journal-title":"J Immunol"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2015.07.102_bib0680","first-page":"14","article-title":"HPV vaccination in Fiji: providing evidence for a reduced dose schedule","volume":"3","author":"Toh","year":"2014","journal-title":"Fiji J Public Health"},{"issue":"August (Suppl 3:S3)","key":"10.1016\/j.vaccine.2015.07.102_bib0685","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vaccine.2006.05.119","article-title":"Chapter 11: HPV vaccines: commercial research & development","volume":"24","author":"Inglis","year":"2006","journal-title":"Vaccine."},{"issue":"June (12)","key":"10.1016\/j.vaccine.2015.07.102_bib0690","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.4049\/jimmunol.174.12.7912","article-title":"B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88","volume":"174","author":"Yang","year":"2005","journal-title":"J Immunol"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2015.07.102_bib0695","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2015.07.102_bib0700","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/mpat.1996.0113","article-title":"Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles","volume":"22","author":"Dupuy","year":"1997","journal-title":"Microbial Pathog"},{"issue":"August (7)","key":"10.1016\/j.vaccine.2015.07.102_bib0705","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"May (27)","key":"10.1016\/j.vaccine.2015.07.102_bib0710","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/j.vaccine.2005.01.146","article-title":"HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood","volume":"23","author":"Pinto","year":"2005","journal-title":"Vaccine"},{"issue":"July (33)","key":"10.1016\/j.vaccine.2015.07.102_bib0715","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.vaccine.2010.06.018","article-title":"Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine","volume":"28","author":"Dauner","year":"2010","journal-title":"Vaccine"},{"issue":"August (33\u201334)","key":"10.1016\/j.vaccine.2015.07.102_bib0720","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15011068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15011068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T05:20:49Z","timestamp":1537420849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15011068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":72,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0264410X15011068"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.102","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}